Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 in Stable IHD and ACS (LILACS)
NCT03113773Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2017
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldesleukin in ischemic heart disease (IHD) and acute coronary syndrome (ACS), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Determination of IL-2 safety and tolerability parameters in Part A at 24 days. Started May 2017; status: completed.
02
Drugs
aldesleukin
03
Conditions
ischemic heart disease (IHD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03113773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113773.